Pham Thuy T T, Ho Dat T, Phan Hai T, Nguyen Toan B, Nguyen Khue M
Department of Hepatology, Medic Medical Center, Ho Chi Minh 700000, Viet Nam.
Department of Imaging Diagnostic, Medic Medical Center, Ho Chi Minh City 700000, Viet Nam.
World J Hepatol. 2025 May 27;17(5):106916. doi: 10.4254/wjh.v17.i5.106916.
The Mac-2 binding protein glycosylated isomer (M2BPGi) is a serum marker for fibrosis that correlates with the fibrosis stages in various liver diseases.
To examine the M2BPGi's threshold for staging fibrosis in patients with chronic hepatitis B (CHB), and its changes during treatment.
This was a prospective, longitudinal study. A total of 348 eligible patients were recruited from the Hepatology Department, Medic Medical Center between March 2020 and December 2023. Liver enzyme tests, platelet counts, M2BPGi levels, and FibroScan were conducted at baseline and at 3-month intervals until six months post-treatment. Correlation plots of M2BPGi, FibroScan, and the other parameters were generated. Receiver operating characteristic curves were constructed for M2BPGi and the other parameters to evaluate their performance.
M2BPGi levels correlated well with FibroScan results and increased as the fibrosis stage advanced. The median M2BPGi levels at the different stages of fibrosis showed statistically significant differences. The cut-off values of M2BPGi for diagnosing significant fibrosis (F ≥ 2), advanced fibrosis (F3), and cirrhosis (F4) were determined to be 1.08, 1.4, and 1.52, respectively. In the context of fibrosis regression in CHB patients during the first 6-month of treatment, M2BPGi levels appeared to decrease before this pattern occurred in the FibroScan results.
M2BPGi levels were strongly correlated with FibroScan. M2BPGi can be used to assess liver fibrosis, and to serve as a tool for monitoring fibrosis regression in CHB patients undergoing treatment.
巨噬细胞2型清道夫受体结合蛋白糖基化异构体（M2BPGi）是一种纤维化血清标志物，与各种肝脏疾病的纤维化阶段相关。
研究慢性乙型肝炎（CHB）患者中M2BPGi用于纤维化分期的阈值及其在治疗过程中的变化。
这是一项前瞻性纵向研究。2020年3月至2023年12月期间，从Medic医疗中心肝病科招募了348例符合条件的患者。在基线时以及治疗后6个月内，每3个月进行一次肝酶检测、血小板计数、M2BPGi水平检测和FibroScan检测。生成了M2BPGi、FibroScan和其他参数的相关性图。构建了M2BPGi和其他参数的受试者工作特征曲线，以评估其性能。
M2BPGi水平与FibroScan结果相关性良好，并随着纤维化阶段的进展而升高。不同纤维化阶段的M2BPGi水平中位数显示出统计学上的显著差异。诊断显著纤维化（F≥2）、进展性纤维化（F3）和肝硬化（F4）的M2BPGi临界值分别确定为1.08、1.4和1.52。在CHB患者治疗的前6个月纤维化消退的情况下，M2BPGi水平似乎在FibroScan结果出现这种模式之前就开始下降。
M2BPGi水平与FibroScan密切相关。M2BPGi可用于评估肝纤维化，并作为监测接受治疗的CHB患者纤维化消退的工具。
